TRUXIMA 100 MG / 10 ML — DIN 02478382
RITUXIMAB : 100 MG / 10 ML · CELLTRION INC. · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is TRUXIMA?
TRUXIMA 100 MG / 10 ML contains RITUXIMAB : 100 MG / 10 ML. It is listed in the Health Canada Drug Product Database under DIN 02478382, held by CELLTRION INC., supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 24-Nov-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TRUXIMA used for?
TRUXIMA™ (rituximab for injection) is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma, CD20 positive, diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) in combination with CHOP chemotherapy, previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP chemotherapy, and maintenance treatment of patients with follicular non-Hodgkin’s lymphoma who have responded to induction therapy. It is also indicated for the treatment of patients with previously untreated or previously treated B-cell chronic lymphocytic leukemia (B-CLL), Binet Stage B or C, in combination with fludarabine and cyclophosphamide. In combination with methotrexate, TRUXIMA™ is indicated in adult patients to reduce signs and symptoms in moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF inhibitor therapies, and in combination with glucocorticoids for the induction of remission in adult patients with severely active Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Rituximab cost around the world?
Rituximab is listed on 13 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 3 | 18 | AUD███.██ |
| South Africa | single exit price | 15 | 15 | ZAR███.██ |
| Romania | max producer price | 12 | 14 | RON███.██ |
| Czechia | max producer price (ex-factory) | 4 | 10 | CZK███.██ |
| Hungary | producer price (ex-factory) | 10 | 10 | HUF███.██ |
| Saudi Arabia | public | 7 | 10 | SAR███.██ |
| United Arab Emirates | public | 8 | 9 | AED███.██ |
| Bahrain | retail (max) | 5 | 9 | BHD███.██ |
| Italy | ex-factory (classe H) | 9 | 9 | EUR███.██ |
| Greece | producer price (ex-factory) | 7 | 7 | EUR███.██ |
| Slovakia | categorised final price | 7 | 7 | EUR███.██ |
| Iceland | max wholesale | 3 | 6 | ISK███.██ |
| Morocco | PPV (public price) | 1 | 2 | MAD███.██ |
126 pack listings across 91 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Rituximab pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Rituximab in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Rituximab, across 8 DINs, of which 7 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| HOFFMANN-LA ROCHE LIMITED | 3 | 3 | RITUXAN, RITUXAN SC | Sourceable in Canada |
| CELLTRION INC. | 2 | 2 | TRUXIMA | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | RUXIENCE | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | RIXIMYO | Sourceable in Canada |
| AMGEN CANADA INC | 1 | 0 | RIABNI | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MG / 10 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Rituximab |
|---|---|
| ATC code | L01FA01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | Yes |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02478382 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2478382 |
| Brand name | TRUXIMA |
| Generic / active ingredient | RITUXIMAB : 100 MG / 10 ML |
| Market authorization holder | CELLTRION INC. |
| Health Canada schedule | Prescription |
| ATC code | L01FA01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01FA |
| Current status | MARKETED |
| Status date | 24-Nov-2025 |
| Original market date | 2019-12-11 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
7 of 8 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| RITUXAN | 10 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02241927 |
| RITUXAN SC | 1400 MG / 11.7 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02457350 |
| RITUXAN SC | 1600 MG / 13.4 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02473976 |
| RIXIMYO | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02498316 |
| RUXIENCE | 10 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02495724 |
| TRUXIMA | 500 MG / 50 ML | SOLUTION | CELLTRION INC. | MARKETED | 02478390 |
| RIABNI | 10 MG | SOLUTION | AMGEN CANADA INC | CANCELLED POST MARKET | 02513447 |
2 · Same class — other molecules in ATC L01FA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Rituximab | RIABNI · RITUXAN · RITUXAN SC · RIXIMYO · +2 more | 8 | 7 | Yes |
| Obinutuzumab | GAZYVA | 1 | 1 | Yes |
| Ofatumumab | ARZERRA | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01F
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01FX | Amivantamab · Belantamab Mafodotin · Blinatumomab · Brentuximab Vedotin · Catumaxomab · +19 more | 36 | 29 |
| L01FD | Pertuzumab · Trastuzumab · Trastuzumab Deruxtecan · Trastuzumab Emtansine | 18 | 16 |
| L01FG | Bevacizumab · Ramucirumab | 14 | 14 |
| L01FF | Atezolizumab · Avelumab · Cemiplimab · Dostarlimab · Durvalumab · +3 more | 14 | 12 |
| L01FC | Daratumumab · Isatuximab | 5 | 5 |
| L01FY | Nivolumab And Relatlimab · Pertuzumab And Trastuzumab | 4 | 4 |
| L01FE | Cetuximab · Necitumumab · Panitumumab | 5 | 3 |
| L01FB | Inotuzumab Ozogamicin | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TRUXIMA called?
The same molecule, Rituximab, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ruxience | Latin | Australia, Bahrain, Czechia, Iceland |
| MABTHERA | Latin | Bahrain, Czechia, Morocco |
| Rixathon | Latin | Bahrain, Czechia, Iceland, Saudi Arabia |
| Riximyo | Latin | Australia |
| MABTHERA SC | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.